U.S. Markets open in 2 hrs 43 mins

Genmab A/S (GEN.CO)

Copenhagen - Copenhagen Real Time Price. Currency in DKK
Add to watchlist
1,414.00+18.00 (+1.29%)
As of 12:47PM CEST. Market open.

Genmab A/S

Bredgade 34E
Copenhagen 1260
45 70 20 27 28

Full Time Employees219

Key Executives

Dr. Jan G. J. van de Winkel Ph.D.Co-Founder, Chief Exec. Officer and Pres14.71MN/A56
Mr. David A. EatwellChief Financial Officer and Exec. VP7.04MN/A56
Ms. Jane JuelSr. Director of Operations & Resource ManagementN/AN/AN/A
Mr. Peter RosSr. Director of Fin. & Accounting and R&D OperationsN/AN/AN/A
Dr. Paul W. H. I. Parren Ph.D.Sr. VP and Scientific DirectorN/AN/A53
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in DKK.


Genmab A/S, a biotechnology company, develops antibody therapeutics for the treatment of cancer in Denmark and internationally. The company markets Arzerra, a human monoclonal antibody for the treatment of chronic lymphocytic leukemia (CCL); and DARZALEX, a human IgG1k monoclonal antibody for the treatment of patients with multiple myeloma (MM). Its products under development include Ofatumumab to treat CLL and follicular lymphoma; Ofatumumab (OMB157) for relapsing remitting multiple sclerosis; and Daratumumab to treat MM, Non-Hodgkin's lymphoma, and solid tumors, as well as natural killer/T-cell lymphoma, nasal type. The company’s products under development also comprise Tisotumab vedotin for treating solid cancers; HuMax-AXL-ADC for solid cancers; Teprotumumab for the treatment of Graves' orbitopathy; AMG 714 for celiac disease; ADCT-301 (HuMax-TAC-ADC) to treat lymphoma and acute myeloid leukemia (AML) or acute lymphoblastic leukemia; JNJ-61186372 for non-small-cell lung cancer; and NJ-63709178 for the treatment of AML. In addition, it has approximately 20 active pre-clinical programs, including naked, bispecific, and immune effector function enhanced antibodies. The company was founded in 1999 and is based in Copenhagen, Denmark.

Corporate Governance

Genmab A/S’s ISS Governance QualityScore as of June 2, 2017 is 4. The pillar scores are Audit: 1; Board: 5; Shareholder Rights: 1; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.